KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBITDA (2016 - 2025)

Historic EBITDA for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$60.2 million.

  • Supernus Pharmaceuticals' EBITDA fell 24746.24% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 16233.19%. This contributed to the annual value of $81.7 million for FY2024, which is 164993.36% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' EBITDA is -$60.2 million, which was down 24746.24% from $12.1 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year EBITDA high stood at $40.8 million for Q3 2024, and its period low was -$60.2 million during Q3 2025.
  • Moreover, its 5-year median value for EBITDA was $8.1 million (2023), whereas its average is $7.9 million.
  • In the last 5 years, Supernus Pharmaceuticals' EBITDA plummeted by 25500.62% in 2023 and then surged by 224909.64% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' EBITDA stood at $6.1 million in 2021, then surged by 463.04% to $34.3 million in 2022, then plummeted by 102.9% to -$996000.0 in 2023, then surged by 2249.1% to $21.4 million in 2024, then plummeted by 381.39% to -$60.2 million in 2025.
  • Its EBITDA was -$60.2 million in Q3 2025, compared to $12.1 million in Q2 2025 and -$10.3 million in Q1 2025.